Last reviewed · How we verify

NCT06096922

AI-based Frailty Assessment Tool for Patients Undergoing Cardiac Surgery

Completed Last updated 28 May 2025
What this trial tests

trial testing No intervention in Frailty in 521 participants. Completed in 31 December 2024.

Timeline
11 May 2023
Primary endpoint
31 December 2024
31 December 2024

Quick facts

Lead sponsorChina National Center for Cardiovascular Diseases
StatusCompleted
Study typeOBSERVATIONAL
Enrollment521
Start date11 May 2023
Primary completion31 December 2024
Estimated completion31 December 2024
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

China National Center for Cardiovascular Diseases — full company profile →

Who can join

18 and older, any sex, with Frailty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main purpose of this study is to establish a frailty automatic evaluation index "AI frailty index" based on artificial intelligence multi-modal non-contact monitoring information analysis. At the same time, the study will explore the correlation between ' AI weakness index ' and perioperative and long-term prognosis and quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Frailty

Currently open trials in the same condition.

Other China National Center for Cardiovascular Diseases trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06096922.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing